Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BBA AVIATION PLC. We currently have 17 research reports from 2 professional analysts.
|01Feb17 07:07||RNS||Completion of disposal of ASIG to John Menzies plc|
|20Jan17 09:25||RNS||Holding(s) in Company|
|03Jan17 11:11||RNS||Block listing Interim Review|
|03Jan17 07:00||RNS||Merger to create US Aircraft Management Business|
|03Jan17 07:00||RNS||Joint Venture|
|21Dec16 15:23||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
BBA AVIATION PLC
BBA AVIATION PLC
N+1 Singer - Morning Song 08-11-2016
08 Nov 16
BBA Aviation (BBA LN) Trading in line; Positive bolt-on | EMIS Group (EMIS LN) Shares oversold, fundamentals intact | First Derivatives (FDP LN) Moving into retail analytics | Grafenia (GRA LN) Conditions remain tough | PCI-PAL (PCIP LN) Special dividend confirmed | Trifast (TRI LN) Another strong performance; forecasts upgraded
N+1 Singer - Morning Song 02-08-2016
02 Aug 16
A G Barr (BAG LN) Weak H1 update. We move to Sell | BBA Aviation (BBA LN) Signature outperforming; ERO still challenging | Dialight (DIA LN) Sales decline and high non u/l costs, but strong cash-flow | Elementis (ELM LN) Challenging H1, well positioned for future recovery | Greggs (GRG LN) A successful first half and a reassuring start to H2 | RhythmOne (RTHM LN) Another positive step | SDL (SDL LN) Building confidence in strategy execution | Spirent Communications (SPT LN) Headwinds mask underlying progress | T. Clarke (CTO LN) Solid H1 performance and confident outlook
N+1 Singer - BBA Aviation - Signature outperforming; ERO still challenging
02 Aug 16
We have said previously that FY16 would be a big year for BBA as they integrate the transformational acquisition of Landmark, look to restructure ERO, work to reduce debt levels and also hope that the US economy remains positive enough to help bizjet activity. So far, the integration of Landmark seems to be progressing well, debt is down to 3.2x EBITDA and ERO remains subdued; on balance, we continue to feel that a group intently focused on business and general aviation will ultimately be a more valuable one and the potential sale of ASIG will be the next positive step. We are encouraged by progress and increase our target price to 253p (c.16x FY16 EPS). We move to Buy.
Solid start to a transformational year
06 May 16
As we said in March, this promises to be a big year and, on balance, we continue to feel that a group intently focused on business and general aviation will ultimately be a more valuable one. Trading is in line with expectations and the integration of Landmark is progressing as planned. Landmark integration and debt reduction remain the keys in FY16 and we await further information on the future of ASIG. We remain at Hold.
06 May 16
BBA Aviation (BBA LN) Solid start to a transformational year | Conviviality (CVR LN) Bibendum – A further upward shift in earnings quality and growth | NCC Group (NCC LN) Revenue strong, margins held back by acquisitions | OMG (OMG LN) Contract win highlights Vicon quality | T. Clarke (CTO LN) Full year outlook reiterated, order book at record high | WYG (WYG LN) Capital markets day highlights scale of international opportunity
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
Time to go over weight
24 Feb 17
We believe equity investors are taking an unnecessarily cautious stance on the construction sector. Forward looking indicators (e.g. consumer confidence, construction PMIs and housing starts) point to a stable market and recent sales LFL are particularly encouraging (e.g. Marshalls). Near term margins may suffer temporary distortions as inflationary pressures build. However, history has shown that modest input cost inflation is actually a positive for earnings growth in the sector. Therefore, as we move into 2018, margin trends are likely to surprise on the upside.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals